SAN DIEGO & TOKYO--(BUSINESS WIRE)-- Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that the first presentation of interim data from a global multi-center Phase 2 study ...
Ambit to Receive a $40 Million Upfront Cash Payment; Up to $350 Million in Pre-Commercialization Milestones, Double-Digit Royalties with Option to Co-promote and Share Profits in U.S. SAN DIEGO and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback